Request Demo
Last update 01 Aug 2026
CKD-702
Last update 01 Aug 2026
Overview
Basic Info
Drug Type Bispecific antibody |
Synonyms CKD 702, CKD702 |
Target |
Action antagonists, inhibitors |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with CKD-702KCT0008025
Phase 1b/2 trial for CKD-702 in combination with irinotecan as a third-line therapy for gastric cancer with MET or EGFR protein overexpression
NCT05750290
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
NCT04667975
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion, Phase I Study to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
100 Clinical Results associated with CKD-702
Login to view more data
100 Translational Medicine associated with CKD-702
Login to view more data
100 Patents (Medical) associated with CKD-702
Login to view more data
100 Deals associated with CKD-702
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Gastroesophageal junction adenocarcinoma | Phase 2 | South Korea | 01 Dec 2022 | |
| Neoplasms | Phase 1 | South Korea | 30 Jan 2022 | |
| metastatic non-small cell lung cancer | Phase 1 | South Korea | 21 May 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
NCT04667975 (ESMO2022) Manual  | Phase 1 | metastatic non-small cell lung cancer EGFR Exon 19 Deletion | EGFR L858R | Met Exon 14 Skipping ... View more | 24 | (All pts) | vhzqdqdnga(fmdlxrzoel) = gpzlwziwbs igjiglbiiq (znjtfzncsk ) View more | Positive | 10 Sep 2022 |
(Met ex14 skipping) | sjozavohkf(nhpafsehvn) = owbdyiigej jnzwyhooyb (sbxfzdnspm ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free